Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market size is expected to reach US$ 8,140.2 Million by 2031 from US$ 1,553.8 Million in 2024. The market is estimated to record a CAGR of 26.9% from 2025 to 2031.

Executive Summary and Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Analysis:

The Asia Pacific cell and gene therapy contract development and manufacturing organization market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The growth of the market is driven by robust infrastructure, supportive policies, and a growing base of CDMOs. Countries like China, Japan, and Singapore are heavily investing in biotechnology innovation, creating a fertile ecosystem for cell and gene therapy development. Governments across the region have introduced supportive regulatory frameworks to fast-track the approval of cell and gene therapies, which encourage early-stage trials and conditional approvals.

Additionally, strategic partnerships, a robust demand for advanced therapeutic solutions, and relatively lower cost of clinical trials and manufacturing in Asia-Pacific-combined with access to large patient populations-makes the region highly attractive to global biopharmaceutical companies seeking CDMO partners. The increasing presence of multinational pharmaceutical companies and collaborations with regional CDMOs have led to rapid infrastructure development, including state-of-the-art GMP manufacturing facilities. Moreover, local CDMOs are expanding their capabilities to support the complex production processes of cell and gene therapies, including viral vector manufacturing, cell processing, and cryopreservation logistics.

Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market: Strategic Insights

Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Segmentation Analysis:

• By Service Type, the Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market is segmented into Drug Development and Manufacturing, Testing and Regulatory Services, and Others. Drug Development and Manufacturing held the largest share of the market in 2024.
• By Product Type, the Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market is segmented into Gene Therapy and Cell Therapy. Gene Therapy held the largest share of the market in 2024.
• By End User, the Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market is segmented into Pharmaceutical Companies, Biopharmaceutical Companies, and Others. Biopharmaceutical Companies held the largest share of the market in 2024.

Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Players Density: Understanding Its Impact on Business Dynamics

The Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Outlook

The demand for cell and gene therapies is driving biopharmaceutical companies toward CDMOs that can provide cutting-edge facilities and technologies, which are required to scale up production while ensuring quality, compliance, and regulatory approval. These specialized capabilities are essential for the production of complex and personalized therapies, which require advanced infrastructure to maintain high manufacturing standards. Cell and gene therapies, including gene editing, viral vector production, and personalized medicine, require specialized facilities equipped with the latest technologies. The production of viral vectors used in gene therapies requires GMP standard facilities to ensure the safety, consistency, and quality of the final product. These facilities should be equipped to handle complex biological materials, such as live cells and genetically modified organisms, in controlled and monitored environments. The increasing adoption of automated cell culture systems, continuous manufacturing, and digital quality monitoring systems enhances the growth and efficiency of gene therapy production. The need for specialized facilities creates a substantial opportunity for CDMOs. It is cost-effective and efficient for biopharma companies to collaborate with CDMOs that have the required technology and facilities. For instance, in 2023, Bristol-Myers Squibb collaborated with a CDMO for the production of its CAR-T cell therapy, Breyanzi. This therapy involves harvesting, modifying, and expanding a patient's T-cells, a process requiring specialized technology and facilities to ensure the desired therapeutic effect. By leveraging CDMO expertise in specialized facilities, Bristol-Myers Squibb was able to scale production while ensuring regulatory compliance and quality. Thus, the soaring need for advanced manufacturing capabilities with advanced technology is expected to create future growth opportunities for the cell and gene therapy contract research and development organization market.

Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Country Insights

By country, the Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market is segmented into China, Japan, India, Australia, South Korea, and the Rest of APAC. China held the largest share in 2024.

China is rapidly emerging as a global leader in cell and gene therapy manufacturing, driven by robust infrastructure, supportive policies, and a growing base of CDMOs. A significant portion of this growth is attributed to domestic CDMOs such as WuXi Biologics and GenScript Biotech, which have established comprehensive cell and gene therapy platforms. WuXi Biologics is a global Contract Research, Development, and Manufacturing Organization (CRDMO) headquartered in Wuxi, China. With over 18 manufacturing sites worldwide, including multiple facilities in China, WuXi Biologics offers comprehensive services across the cell and gene therapy value chain. In 2021, the company unveiled its MFG5 facility in Wuxi, featuring a 60,000-liter single-use bioreactor capacity, underscoring China's growing capabilities in large-scale cell and gene therapy production. Additionally, GenScript Biotech launched its new CDMO segment under the brand name "ProBio" at the inaugural GenScript Cell and Gene Therapy Industry Development and Cooperation Forum. Through ProBio, the company has also made significant strides in cell and gene therapy manufacturing. The company has developed an integrated cell therapy platform and has attracted substantial investment to expand its capabilities, positioning itself as a significant player in China's cell and gene therapy sector. In December 2024, the company inaugurated China's largest commercial GMP plasmid manufacturing facility in Zhenjiang, Jiangsu Province. Spanning 6,400 m2, this state-of-the-art facility offers comprehensive services from preclinical studies to commercial-scale production, supporting the rapid development of mRNA and viral vector-based therapies.

Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Company Profiles

Some of the key players operating in the market include Charles River Laboratories International Inc, Catalent Inc, Lonza Group AG, WuXi Biologics Inc, Pluri Inc, Aenova Holding GmbH, Takara Bio Inc, FUJIFILM Holdings Corp, AGC Biologics AS, Thermo Fisher Scientific Inc., Minaris Advanced Therapies, and SK pharmteco Inc.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note: All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise